awmsg logo



fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®)


Reference No. 1216

Publication date:
14/08/2014


Appraisal information

fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®) 184 micrograms/22 micrograms inhalation powder
fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®) 92 micrograms/22 micrograms inhalation powder


Company: GlaxoSmithKline
BNF category: Respiratory system
NMG meeting date: 18/06/2014
AWMSG meeting date: 16/07/2014
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 2014
Ministerial ratification: 13/08/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Fluticasone furoate/vilanterol (Relvar® Ellipta®) is recommended as an option for use within NHS Wales for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download